Voyager Therapeutics Total Liabilities 2014-2022 | VYGR

Voyager Therapeutics total liabilities from 2014 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Voyager Therapeutics Annual Total Liabilities
(Millions of US $)
2021 $99
2020 $107
2019 $255
2018 $131
2017 $50
2016 $54
2015 $60
2014 $10
2013 $4
Voyager Therapeutics Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $148
2021-12-31 $99
2021-09-30 $97
2021-06-30 $98
2021-03-31 $102
2020-12-31 $107
2020-09-30 $104
2020-06-30 $221
2020-03-31 $243
2019-12-31 $255
2019-09-30 $268
2019-06-30 $270
2019-03-31 $311
2018-12-31 $131
2018-09-30 $131
2018-06-30 $133
2018-03-31 $137
2017-12-31 $50
2017-09-30 $56
2017-06-30 $53
2017-03-31 $52
2016-12-31 $54
2016-09-30 $53
2016-06-30 $54
2016-03-31 $56
2015-12-31 $60
2015-09-30 $65
2015-06-30 $0
2015-03-31 $0
2014-12-31 $10
2014-09-30 $0
2014-06-30
2014-03-31
2013-12-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.245B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00